Try our mobile app
Screener
Company
Price and
change
Revenue Growth
last / hist
EV /
LTM
EBITDA
(p75)
EV/
Sales
EBITDA LTM
/ Revenue
FCF LTM
/ Revenue
Next GAAP report
Year div-d yield
FCF Yield LTM
200.0%  /
57.6%
>200x
>200x
-0.2x
8.3%
-105.6%
..
0.0%
-950.0% 
0.0%  /
31.2%
0.6x
1.2x
0.3x
50.0%
27.3%
2025-11-17
0.0%
60.0% 
100.0%  /
29.2%
>200x
0.3x
0.8x
-100.0%
-116.7%
..
0.0%
-77.8% 
6.2%  /
25.9%
>200x
>200x
1.6x
-3.7%
1.5%
..
0.0%
0.9% 
134.7%  /
24.8%
10.5x
7.9x
0.9x
8.2%
-12.9%
..
0.0%
-21.3% 
15.7%  /
16.0%
12.4x
12.3x
2.3x
18.8%
-6.1%
2025-11-17
1.3%
-2.6% 
0.0%  /
12.6%
14.9x
6x
0.8x
0.0%
5.3%
..
23.3%
11.1% 
17.6%  /
11.8%
6.8x
8.3x
1.3x
19.2%
-5.4%
..
9.8%
-3.2% 
15.9%  /
9.2%
17.3x
18.2x
4.8x
28.0%
-0.6%
2026-02-28
0.0%
-0.2% 
10.7%  /
8.9%
17.5x
16.7x
4.1x
23.4%
-5.5%
2026-02-21
1.2%
-1.5% 
8.5%  /
7.5%
13.7x
12.7x
1.8x
13.1%
-4.0%
..
0.9%
-3.4% 
22.9%  /
6.2%
63x
62.8x
11.9x
18.9%
9.0%
..
1.4%
0.7% 
-11.6%  /
2.0%
1.8x
3.8x
0.8x
47.3%
1.4%
..
10.4%
0.7% 
-2.6%  /
0.9%
9.7x
17.6x
0.8x
8.5%
-2.7%
2026-02-05
0.0%
-4.9% 
4.3%  /
-4.6%
12.8x
27.6x
2.9x
22.8%
12.5%
2026-02-28
2.7%
8.8% 
Trending screeners:
@electric-vehicles
@saas
@cannabis-players
@china
Latin America
India
Dividends
@REITs
@adtech
@airlines
@artificial-intelligence
@auto-parts
@cloud-computing
@crypto
@cybersecurity
@e-commerce
@edtech
@finance-and-technology
@gaming
@internet-of-things
@oil-refining
@real-estate-tech
@renewable-energy
@vaccine-makers

Reviews

2025-11-15
#reports #VNRX

[VolitionRx Limited](https://eninvs.com/all.php?name=VNRX) (Diagnostics and Research) reported for [2025 q3](https://eninvs.com/press_release.php?source=sec&form_type=10&id=194251)
(2025-11-13, After Market Close):

- Revenue +32% YoY (vs +2.8% in previous quarter and historical rate +103.8%)
- EBITDA margin -774.0% increased compared to -1175.6% same period last year
- Net Debt increased by $2 bln since the start of the year (6279.1% of market cap)
- FCF (LTM) -$8.9 bln (negative), 27728.9% of market cap
- EV/Sales multiple is 6.9x

At the opening of the session the share price went up +3.3% vs S&P500 -1.1%
2025-11-15
#reports #FEMY

[Femasys Inc.](https://eninvs.com/all.php?name=FEMY) (Medical Instruments and Supplies) reported for [2025 q3](https://eninvs.com/press_release.php?source=sec&form_type=10&id=194247)
(2025-11-06, After Market Close):

- Revenue +31.4% YoY (vs +85.1% in previous quarter and historical rate +54.0%)
- EBITDA margin -489.4% increased compared to -908.5% same period last year
- Net Debt decreased by $776 mln over the past reporting period (7318.9% of market cap)
- FCF (LTM) -$5 bln (negative), 47233.2% of market cap
- EV/Sales multiple is 1.2x

At the opening of the session the share price went down -0.2% vs S&P500 -0.4%
2025-11-15
#reports #OMI

[Owens & Minor](https://eninvs.com/all.php?name=OMI) (Logistic services provider) reported for [2025 q3](https://eninvs.com/press_release.php?source=sec&form_type=10&id=194224)
(2025-10-30, Before Market Open):

- Revenue -74.4% YoY (vs -74.5% in previous quarter and historical rate -9.6%)
- EBITDA +5.8% YoY (vs -76.2% in previous quarter and historical rate -20.5%)
- EBITDA margin 13.1% increased compared to 3.2% same period last year
- Net Debt increased by $144 mln over the past reporting period (81.2% of market cap)
- FCF (LTM) +$0.1 bln (positive), 62.0% of market cap
- EV/Sales multiple is 0.3x

At the opening of the session the share price went down -1.3% vs S&P500 -0.4%
2025-11-15
#reports #HSON

[Hudson Global](https://eninvs.com/all.php?name=HSON) (Staffing and Employment Services) reported for 2025 q3
(2025-08-08, Before Market Open):

- Revenue +29.7% YoY (vs 0.0% in previous quarter and historical rate +7.8%)
- EBITDA margin -4.2% decreased compared to 0.0% same period last year
- Net Debt increased by $24 mln over the past reporting period (90.7% of market cap)
- EV/Sales multiple is 0.2x

At the opening of the session the share price went up +3.1% vs S&P500 +0.2%
2025-11-15
#reports #XTNT

[Xtant Medical](https://eninvs.com/all.php?name=XTNT) (Medical Devices) reported for [2025 q3](https://eninvs.com/press_release.php?source=sec&form_type=10&id=194103)
(2025-11-03, Before Market Open):

- Revenue +17.9% YoY (vs +16.7% in previous quarter and historical rate +35.7%)
- EBITDA margin 12.1% increased compared to -10.7% same period last year
- Net Debt decreased by $27 mln over the past reporting period (29.1% of market cap)
- FCF (LTM) +$0 bln (positive), 1.1% of market cap
- EV/EBITDA multiple is 8.3x compared to historical level (75th percentile) of 33.3x
- EV/Sales multiple is 0.7x

At the opening of the session the share price went up +0.1% vs S&P500 +0.6%
2025-11-15
#reports #XBIO

[Xenetic Biosciences](https://eninvs.com/all.php?name=XBIO) (Biotechnology) reported for [2025 q3](https://eninvs.com/press_release.php?source=sec&form_type=10&id=194100)
(2025-08-12, Before Market Open):

- Revenue +67.3% YoY (vs -18.7% in previous quarter and historical rate +49.9%)
- EBITDA margin -52.2% increased compared to -80.0% same period last year
- Net Debt increased by $658 mln over the past reporting period (16410.8% of market cap)
- FCF (LTM) -$2.1 bln (negative), 51377.2% of market cap
- EV/EBITDA multiple is 7.4x compared to historical level (75th percentile) of 4.7x
- EV/Sales multiple is -1.4x

2025-11-15
#reports #VRME

[VerifyMe](https://eninvs.com/all.php?name=VRME) (Security and Protection Services) reported for [2025 q3](https://eninvs.com/press_release.php?source=sec&form_type=10&id=194099)
(2025-11-05, Before Market Open):

- Revenue 0% YoY (vs 0.0% in previous quarter and historical rate +31.2%)
- Net Debt increased by $1 mln over the past reporting period (9.9% of market cap)
- FCF (LTM) +$0 bln (positive), 69.3% of market cap
- EV/EBITDA multiple is 0.6x compared to historical level (75th percentile) of 1.2x
- EV/Sales multiple is 0.3x

At the opening of the session the share price went up +2.2% vs S&P500 -0.1%
2025-11-15
#reports #UTMD

[Utah Medical Products](https://eninvs.com/all.php?name=UTMD) (Medical Instruments and Supplies) reported for [2025 q3](https://eninvs.com/press_release.php?source=sec&form_type=10&id=194098)
(2025-05-15, Before Market Open):

- Revenue 0% YoY (vs 0.0% in previous quarter and historical rate +3.0%)
- EBITDA +66.7% YoY (vs 0.0% in previous quarter and historical rate -2.0%)
- EBITDA margin 50.0% increased compared to 30.0% same period last year
- Net Debt decreased by $2 mln over the past reporting period (1.0% of market cap)
- FCF (LTM) +$0.3 bln (positive), 151.8% of market cap
- EV/EBITDA multiple is 7.3x compared to historical level (75th percentile) of 12.1x
- EV/Sales multiple is 3x

At the opening of the session the share price went up +1.7% vs S&P500 -0.4%
2025-11-15
#reports #TPIC

[TPI Composites](https://eninvs.com/all.php?name=TPIC) (Industrial company) reported for [2025 q3](https://eninvs.com/press_release.php?source=sec&form_type=10&id=194096)
(2025-08-11, After Market Close):

- Revenue -38.6% YoY (vs -11.0% in previous quarter and historical rate -9.8%)
- EBITDA margin -33.3% decreased compared to -1.0% same period last year
- Net Debt decreased by $147 mln over the past reporting period (2432.0% of market cap)
- FCF (LTM) -$0 bln (negative), 165.4% of market cap
- EV/Sales multiple is 0.4x

At the opening of the session the share price went down -23.3% vs S&P500 +0.3%
2025-11-15
#reports #TELA

[TELA Bio](https://eninvs.com/all.php?name=TELA) (Medical Devices) reported for [2025 q3](https://eninvs.com/press_release.php?source=sec&form_type=10&id=194092)
(2025-11-13, After Market Close):

- Revenue +10.5% YoY (vs +25.0% in previous quarter and historical rate +29.5%)
- EBITDA margin -33.3% increased compared to -47.4% same period last year
- Net Debt increased by $43 mln over the past reporting period (94.9% of market cap)
- FCF (LTM) +$0.1 bln (positive), 121.3% of market cap
- EV/Sales multiple is 0.7x

At the opening of the session the share price went down -5.4% vs S&P500 -1.1%
2025-11-15
#reports #SMWB

[Similarweb Ltd.](https://eninvs.com/all.php?name=SMWB) (Internet Content and Information) reported for 2025 q3
(2025-11-11, After Market Close):

- Revenue +10.8% YoY (vs +16.4% in previous quarter and historical rate +14.0%)
- EBITDA margin -4.2% decreased compared to -3.1% same period last year
- Net Debt decreased by $5 mln over the past reporting period (0.9% of market cap)
- FCF (LTM) +$0 bln (positive), 0.7% of market cap
- EV/Sales multiple is 1.9x

At the opening of the session the share price went down -15.1% vs S&P500 +0.3%
2025-11-15
#reports #SBH

[Sally Beauty](https://eninvs.com/all.php?name=SBH) (Professional cosmetics supplier ) reported for [2025 q3](https://eninvs.com/press_release.php?source=sec&form_type=10&id=194083)
(2025-11-13, Before Market Open):

- Revenue +1.3% YoY (vs -1.0% in previous quarter and historical rate -1.0%)
- EBITDA -2.4% YoY (vs +3.0% in previous quarter and historical rate +6.1%)
- EBITDA margin 8.4% decreased compared to 8.8% same period last year
- Net Debt increased by $16 mln over the past reporting period (1.1% of market cap)
- FCF (LTM) +$0.7 bln (positive), 47.4% of market cap
- EV/EBITDA multiple is 7x compared to historical level (75th percentile) of 8x
- EV/Sales multiple is 0.8x

At the opening of the session the share price went up +6.8% vs S&P500 -0.4%
2025-11-15
#reports #RKDA

[Arcadia Biosciences](https://eninvs.com/all.php?name=RKDA) (Agricultural Inputs) reported for [2025 q3](https://eninvs.com/press_release.php?source=sec&form_type=10&id=194081)
(2025-11-07, After Market Close):

- Revenue -50% YoY (vs 0.0% in previous quarter and historical rate -21.5%)
- EBITDA margin -100.0% has not changed compared to -100.0% same period last year
- Net Debt decreased by $2 mln over the past reporting period (38.8% of market cap)
- FCF (LTM) -$0 bln (negative), 77.7% of market cap
- EV/Sales multiple is -0.2x

At the opening of the session the share price went down -2.7% vs S&P500 +1.1%
2025-11-15
#reports #REKR

[Rekor Systems](https://eninvs.com/all.php?name=REKR) (Software — Infrastructure) reported for [2025 q3](https://eninvs.com/press_release.php?source=sec&form_type=10&id=194079)
(2025-11-13, After Market Close):

- Revenue +27.3% YoY (vs 0.0% in previous quarter and historical rate +45.7%)
- EBITDA margin -21.4% increased compared to -109.1% same period last year
- Net Debt increased by $1 mln over the past reporting period (0.9% of market cap)
- FCF (LTM) +$0 bln (positive), 3.8% of market cap
- EV/Sales multiple is 2.5x

At the opening of the session the share price went down -4.4% vs S&P500 -1.1%
2025-11-15
#reports #QUIK

[QuickLogic Corporation](https://eninvs.com/all.php?name=QUIK) (Semiconductors) reported for [2025 q3](https://eninvs.com/press_release.php?source=sec&form_type=10&id=194076)
(2025-11-11, After Market Close):

- Revenue -50% YoY (vs 0.0% in previous quarter and historical rate +9.3%)
- EBITDA margin -150.0% decreased compared to -25.0% same period last year
- Net Debt increased by $2 mln over the past reporting period (2.1% of market cap)
- FCF (LTM) +$0 bln (positive), 6.2% of market cap
- EV/Sales multiple is 6x

At the opening of the session the share price went down -5.7% vs S&P500 +0.3%
2025-11-15
#reports #PXLW

[Pixelworks](https://eninvs.com/all.php?name=PXLW) (Semiconductors) reported for [2025 q3](https://eninvs.com/press_release.php?source=sec&form_type=10&id=194073)
(2025-11-11, After Market Close):

- Revenue -10% YoY (vs -11.1% in previous quarter and historical rate -17.2%)
- EBITDA margin -55.6% increased compared to -80.0% same period last year
- Net Debt increased by $1 mln over the past reporting period (0.3% of market cap)
- FCF (LTM) -$0 bln (negative), 2.4% of market cap
- EV/Sales multiple is 12.7x

At the opening of the session the share price went up +3.8% vs S&P500 +0.3%
2025-11-15
#reports #PRPO

[Precipio](https://eninvs.com/all.php?name=PRPO) (Diagnostics and Research) reported for [2025 q3](https://eninvs.com/press_release.php?source=sec&form_type=10&id=194071)
(2025-08-13, After Market Close):

- Revenue +40% YoY (vs +20.0% in previous quarter and historical rate +59.2%)
- EV/Sales multiple is 20.5x

At the opening of the session the share price went up +0.8% vs S&P500 -0.2%
2025-11-15
#reports #NUWE

[Nuwellis](https://eninvs.com/all.php?name=NUWE) (Medical Devices) reported for [2025 q3](https://eninvs.com/press_release.php?source=sec&form_type=10&id=194064)
(2025-08-14):

- Revenue 0% YoY (vs 0.0% in previous quarter and historical rate +1.4%)
- EBITDA margin -150.0% decreased compared to -50.0% same period last year
- Net Debt decreased by $13 mln over the past reporting period (110.1% of market cap)
- FCF (LTM) -$0 bln (negative), 110.1% of market cap
- EV/Sales multiple is 2.2x

2025-11-15
#reports #MYSZ

[My Size](https://eninvs.com/all.php?name=MYSZ) (Software — Application) reported for [2025 q3](https://eninvs.com/press_release.php?source=sec&form_type=10&id=194062)
(2025-08-14):

- Revenue +50% YoY (vs 0.0% in previous quarter and historical rate +59.7%)
- EBITDA margin -33.3% increased compared to -50.0% same period last year
- EV/Sales multiple is -0.1x

2025-11-15
#reports #LPSN

[LivePerson](https://eninvs.com/all.php?name=LPSN) (Software provider) reported for [2025 q3](https://eninvs.com/press_release.php?source=sec&form_type=10&id=194054)
(2025-11-05, After Market Close):

- Revenue -18.9% YoY (vs -25.0% in previous quarter and historical rate -17.4%)
- EBITDA margin -15.0% decreased compared to -9.5% same period last year
- Net Debt decreased by $80 mln over the past reporting period (253.9% of market cap)
- FCF (LTM) -$0 bln (negative), 152.3% of market cap
- EV/Sales multiple is 1.3x

At the opening of the session the share price went up +2.7% vs S&P500 -0.4%
2025-11-15
#reports #KPTI

[Karyopharm Therapeutics](https://eninvs.com/all.php?name=KPTI) (Biotechnology) reported for [2025 q3](https://eninvs.com/press_release.php?source=sec&form_type=10&id=194051)
(2025-08-11, Before Market Open):

- Revenue +12.8% YoY (vs -11.6% in previous quarter and historical rate -8.9%)
- EBITDA margin -31.8% increased compared to -66.7% same period last year
- Net Debt increased by $12 mln over the past reporting period (1.7% of market cap)
- FCF (LTM) -$0.1 bln (negative), 11.7% of market cap
- EV/Sales multiple is 6x

At the opening of the session the share price went up +1.5% vs S&P500 0.0%